The 1st step in the posttranslational hypusine [N ε -(4-amino-2-hydroxybutyl)lysine] modification of eukaryotic translation initiation factor 5A (eIF5A) is catalyzed by deoxyhypusine synthase (DHS). The eIF5A intermediate is subsequently hydroxylated by deoxyhypusine hydroxylase (DHH), thereby converting the eIF5A precursor into a biologically active protein. Depletion of eIF5A causes inhibition of cell growth, and the identification of eIF5A as a cofactor of the HIV Rev protein turns this host protein and therefore DHS into an interesting target for drugs against abnormal cell growth and/or HIV replication. The authors developed a 96-well format DHS assay applicable for the screening of DHS inhibitors. Using this assay, they demonstrate DHS inhibition by AXD455 (Semapimod, CNI-1493). This assay represents a powerful tool for the identification of new DHS inhibitors with potency against cancer and HIV. (Journal of Biomolecular Screening 2004:434-438) 
INTRODUCTION
A UNIQUE 2-STEP POSTTRANSLATIONAL MODIFICATION leads to the formation of hypusine [N ε -(4-amino-2-hydroxybutyl)lysine], which occurs only in 1 known cellular protein, the precursor of eukaryotic translation initiation factor 5A (eIF5A). 3, 4 The 1st step of this reaction is catalyzed by deoxyhypusine synthase (DHS), which mediates the NAD-dependent transfer of the butylamine moiety of the polyamine spermidine to the ε-amino group of a single lysine residue in the eIF5A precursor protein (Lys 50 in the human precursor) to form deoxyhypusine. Hydroxylation of this intermediate by deoxyhypusine hydroxylase (monooxygenase) completes hypusine formation and eIF5A maturation. 3, 4 Human eIF5A is a 154 amino acid protein with a molecular mass of 16.7 kDa. Studies in the yeast Saccharomyces cerevisiae have demonstrated that fully modified eIF5A is required for eukaryotic cell proliferation, but its function is not fully understood yet. 1, 5 Treatment of human umbilical vein endothelial cells (HUVEC) with the spermidine-related compound N1-guanyl-1,7-diaminoheptane (GC7), a DHS inhibitor, leads to a dose-dependent inhibition of hypusine formation and cellular proliferation, 6 suggesting an important role for DHS in cell growth. Recent data characterize eIF5A as a nucleocytoplasmic shuttle protein, which is actively exported from the nucleus, 7, 8 and its hypusine modification seems to be involved in this process. 7 Furthermore, eIF5A was identified as a cellular cofactor of the HIV-1 Rev regulatory protein, 9 playing an essential role in the nucleocytoplasmic translocation of Rev and Rev-mediated viral RNA export. 2, 10, 11 The Rev protein shuttles constantly between the nucleus and the cytoplasm of host cells, thereby mediating the transport of unspliced and incompletely spliced viral mRNA into the cytoplasm. This is a necessary step to produce progeny virus. 12 Distinct eIF5A mutants have been described that block Rev activity and thereby HIV-1 replication in human T cells in trans. 2, 13 Therefore, blocking the biological activity of eIF5A by inhibiting the DHS-mediated hypusine modification of the eIF5A precursor protein should provide a novel strategy to block HIV-1 replication. Moreover, novel DHS inhibitors may also be useful agents in the therapy of tumorigenic diseases such as, for example, lung adenocarcinomas. 14 In this note, we describe the development of a screening assay for the measurement of DHS activity in a 96-well plate format, which is well suited for the discovery of novel DHS inhibitors.
MATERIALS AND METHODS

Reagents and plasmids
NAD +
, glutathione (GSH, reduced form of glutathione), Dithiothreitol (DTT), PMSF, aprotinin, leupeptin, imidazole, and spermidine were purchased from Sigma (Taufkirchen, Germany). IPTG was ordered from Biomol (Hamburg, Germany). Nonidet P40 and factor Xa were supplied from Roche (Mannheim, Germany). Triton X-100 was ordered from Roth (Karlsruhe, Germany). DNaseI and lysozyme were purchased from Boehringer (Mannheim, Germany). Glycine, DMSO, and all other chemicals were from Merck (Darmstadt, Germany). Radio-labeled [ 14 C]-spermidine trihydrochloride was from Amersham Pharmacia (Freiburg, Germany). The construct pGEX-eIF5A has been described elsewhere. 2 The plasmid expressing histidine-tagged DHS was constructed by inserting a PCR-generated human DHS cDNA between the BamHI and EcoRI sites of the bacterial expression vector pTrcHisC (Invitrogen, Karlsruhe). AXD455 (Semapimod, CNI-1493) was from Vichem Kft (Budapest, Hungary).
Protein production and purification
Expression and purification of eIF5A
eIF5A was expressed as a glutathione S transferase (GST) fusion protein in E. coli DH-5α. A 2.5 l culture of LB-ampicillin medium was inoculated with a 250 ml overnight culture of E. coli DH-5α transformed with pGEX-eIF5A and grown at 37°C. When OD 600 of 0.8 was reached, expression was induced by the addition of 0.5 mM IPTG, and the cultures were incubated for a further 4 h at 37°C. Bacteria were harvested by centrifugation (10 min, 5000 g, 4°C) and stored at -80°C.
Cell pellets were resuspended in 100 ml PBS, 0.1 mM PMSF, leupeptin (2 µg/ml), aprotinin (2 µg/ml), and DNaseI (0.5 µg/ml). Small amounts of lysozyme, 2.6 mM MnCl 2 , and 26 mM MgCl 2 were added, and the lysate was incubated for 15 min on ice. Subsequently the lysate was sonicated (3 × 10 sec and 2 × 30 sec); 0.5 M NaCl and 1% Triton X-100 were added and the lysate was again incubated on ice for 10 min. Insoluble cell debris was removed by centrifugation (30 min at 4°C with 30,000 g). Small-scale purification was performed in batch (see below). For large-scale purification, the supernatant was applied to a glutathione-sepharose™ 4 fast flow column (Amersham-Biosciences) using Äkta-Purifier, and GST-eIF5A was eluted with glutathione elution buffer (50 mM Tris/HCl, pH 8.0, 0.1% Triton X-100, 0.1 M NaCl, 1 mM DTT, and 50 mM reduced glutathione). Fractions containing purified GST-eIF5A were pooled and dialyzed overnight at 4°C against factor Xa cleavage buffer (50 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1 mM CaCl 2 ). After determination of protein concentration (BCA-Kit, Pierce), GST-eIF5A was subjected to factor Xa cleavage for 16 h at ambient temperature (RT). A ratio of 1/200 of factor Xa to GST-eIF5A (in µg) was used for cleavage. Liberated GST was then captured by an additional incubation with glutathione-sepharose (overnight in batch) leaving native eIF5A in the supernatant after centrifugation (3 min, 500 g, 4°C). Finally, cleaved eIF5A was dialyzed against the assay buffer (0.3 M glycine-NaOH buffer, pH 9.0).
Batch purification of eIF5A
The supernatant was incubated overnight with 1 ml preequilibrated glutathione-sepharose™ 4B (Amersham-Biosciences). Subsequently, the beads were washed 3 times with PBS, and GSTeIF5A was eluted 5 times with each 1 ml glutathione elution buffer. Further purification was as described above.
Expression and purification of DHS
N-terminally His-tagged DHS was expressed in E. coli DH-5α (BL-21-DE3-Codon Plus) transformed with pTrc-DHS following the procedure described for eIF5A. Cell pellets were resuspended in lysis buffer (20 mM Tris/HCl, pH 7.7, 500 mM NaCl, 5 mM imidazole, 0.1 mM PMSF, 0.2 µg/ml leupeptin, 0.2 µg/µl aprotinin, 0.5 µg/ml DNaseI, and 1% NP-40). Cells were lysed by sonication (3 × 10 s and 2 × 30 s), and insoluble cell debris was removed by centrifugation (30 min, 30,000 g, 4°C) . Small-scale purification was done in batch: supernatant was incubated for 1 h with 1 ml of Ni-NTA beads from Qiagen (pre-equilibrated in lysis buffer). Subsequently the beads were washed 3 times with lysis buffer, and His-DHS was eluted by a stepwise rise in imidazole concentration (25 mM, 75 mM, and 250 mM imidazole in lysis buffer). For large-scale purification, His-DHS was applied to chelating-sepharose™ fast flow (Amersham-Biosciences) (coupled with 0.1 M NiSO 4 ) and purified by Äkta-Purifier. The column was washed with lysis buffer, and His-DHS was then eluted with a linear gradient of the DHS elution buffer (lysis buffer with 1 M imidazole). Finally His-DHS was dialyzed against assay buffer.
DHS assay
A previously published filter-binding assay 15 was modified and adapted to a 96-well format. The reaction mixture contained 5 µg eIF5A (concentration measured by SDS-PAGE, Coomassie staining and comparison to BSA standards), 0.5 µCi (4.46 nmol) [ 14 C]-spermidine trihydrochloride (112 mCi/mmol), 1 mM nicotinamide adenine dinucleotide (NAD + ), 1 mM DTT, 1 µl DMSO or inhibitor, and indicated amounts of the purified DHS in 0.3 M glycine-NaOH buffer, pH 9.0 (total volume 101 µl). After 1 h incubation at RT, incorporation of radio-labeled aminobutylidene was terminated by the addition of 50 µl 20 mM spermidine in PBS; 50 µl of stopped reaction were transferred to a humidified MAIP NOB 96-well filter plate (Millipore), followed by a 30-min incubation step (RT) to allow complete binding of all proteins to the filters. Subsequently, filter plates were evacuated using a Multi Screen R Resist Vacuum Manifold (Millipore). The filters were washed twice with 200 µl per well of 20 mM spermidine in PBS, followed by 2 washes with 200 µl PBS per well. The filters were dried at RT, and 25 µl scintillation cocktail (OptiPhase "SuperMix" from PerkinElmer/Wallac) were added to each dried filter. The plate measurement started with a delay of 30 min incubation in the dark using a Microbeta (PerkinElmer/Wallac).
DHS kinetics
Assays were performed as described above varying the amount of DHS, to determine the optimal DHS amount. The following amounts were used for this experiment: 1 µg, 0.5 µg, 0.25 µg, 0.125 µg, and 0.0625 µg per assay.
AXD455 dose response
The assay was performed as described above using increasing concentration of AXD455 (Semapimod).
Z calculation
Z′ = 1 -((3*σC+ + 3*σC-)/∆S).
RESULTS AND DISCUSSION
Production of recombinant His-tagged deoxyhypusine synthase (DHS) and eIF5A
His-DHS and GST-eIF5A were expressed in bacteria after induction with IPTG. Proteins were purified in small scale to test for optimal expression conditions. Subsequently, large-scale purification was performed using the Äkta-Purifier as described in the materials and methods section. DHS purification was effective, revealing a protein of the expected molecular mass of nearly 41 kDa. His-DHS could be eluted from Ni-NTA-beads by 250 mM imidazole (Fig. 1, lanes 8 and 9) . In large-scale production, we were able to routinely produce 500 µg DHS per 1 liter bacterial culture. The induction of GST-eIF5A resulted in an enormous expression of the 43 kDa fusion protein, which is visualized in Figure  2A (lanes 6-10) . GST-eIF5A fusion protein is only a poor substrate for DHS, because the amino terminal GST moiety appears to interfere with the DHS-catalyzed modification of Lys 50 in the eIF5A precursor (data not shown). Therefore, the GST-tag had to be removed by digestion of the fusion protein with factor Xa. This resulted in 2 bands, the 26 kDa GST and the 16.7 kDa eIF5A precursor protein (Fig. 2B) . Routinely we were able to recover~6 mg eIF5A per liter bacterial culture.
Measurement of DHS activity
The ultimate goal in the development of a drug-screening assay is the establishment of a simple high-capacity test system that provides accurate and reproducible data. We adapted a previously described filter-binding assay 15 to 96-well format. For optimization of the enzyme consumption, we first performed DHS kinetics. Varying the amount of DHS per reaction from 0.0625 µg to 1.0 µg clearly correlated with a significant increase in labeled eIF5A protein (Fig. 3) . The reaction appeared to be linear over the range of 0.15 to 0.5 µg of input DHS. Therefore, the subsequent routine experiments were performed using 0.35-0.45 µg of DHS protein.
Inhibition of DHS by AXD455
We next used AXD455 (Fig. 4A) as a test compound to characterize the validity of this 96-well assay for the identification of potentially novel DHS inhibitors. Increasing the concentration of AXD455 from 0.4 µM to 10 µM results in a dose-dependent inhi- bition of DHS activity (Fig. 4B) , which reflects the sensitivity of this assay. The IC 50 of AXD455 was in the range of 1.5 to 2.5 µM, compared to~6 µM determined using the previous assay. Between multiple plates, the Z′ of this assay was determined to be > 0.6. This underlines the successful adaptation of the DHS assay to the 96-well format.
Reflecting the prevailing strategy for the therapy of HIV infections involves primarily HIV proteins as drug-targets, inherently bearing the problem of drug resistance. 16, 17 Therefore, new strategies are required to pharmaceutically attack HIV infections. Such a strategy could be based on the development of inhibitors targeted against host cell activities that are important for virus replication, and this would even allow the treatment of patients that already harbor multiple antiretroviral drug-resistant viruses.
As mentioned before, eIF5A is a cellular cofactor of the HIV-1 Rev protein, 9 and its unique hypusine modification performed by DHS seems to be essential for its biological activity. 3, 4 Therefore, the identification of DHS inhibitors, like AXD455, could be one step in the development of new HIV therapies. 
